Microarray-based Glycoproteomics Service
Overview
As a trusted supplier in the field of microarrays, CD BioGlyco is committed to designing and developing various effective biological microarray products and providing corresponding testing services. Our microarray detection platform provides a full range of microarray-based analysis services to help our customers reduce costs while using advanced technologies for related research. We are confident to provide you with high-quality products and high-quality services to accelerate the output of research results.
Lectin microarray and Biomarker Discovery
Carbohydrate post-translational modifications on proteins are important determinants of protein function in normal and disease biology. Protein glycosylation is the enzymatic addition of sugars or oligosaccharides to proteins. Altered glycosylation usually occurs in the early stages of disease development. For example, certain tumor-associated glycans have been shown to be expressed in the precursor lesions of different types of cancer and have become powerful early diagnostic markers. A variety of lectins can be used as detection probes, and each probe is directed to a different glycan group to establish a lectin binding profile for the capture protein. The antibody array used for glycan detection is very effective for analyzing the variation of specific glycans on a variety of proteins. The main goal of the high-throughput analysis is usually related to the identification of novel biomarkers with therapeutic and/or diagnostic value. Lectin microarray technology is expected to become an important tool for glycosylation research and identification of tumor cell surface markers. Efficient and multiple studies are performed on the glycans of a single protein in a complex mixture. The antibody microarrays of multiple proteins are used to capture, and then lectin or glycan-binding antibodies are used for detection.
Key Technologies
- Lectin Microarrays
Lectin microarrays constitute foundational elements within our analytical platform. We deploy an expansive array of lectins – carbohydrate-binding proteins exhibiting discrete specificity for defined glycotopes – to interrogate intricate glycan topologies within a singular, multiplexed assay. This methodology facilitates the concurrent, expeditious interrogation of manifold lectin-glycan recognition events, furnishing an exhaustive representation of a specimen's glycomic signature. Lectin microarrays prove exceptionally potent for expansive screening initiatives and discerning pathological glycoform aberrations.
- Protein Microarrays
Protein microarrays complement our analytical arsenal. These substrates, arrayed with multitudinous distinct probes encompassing antibodies and lectins, facilitate the selective sequestration of discrete glycoproteins from convoluted biological matrices. This targeted capture mechanism enables focused scrutiny of protein-glycan interplay. This replicable, highly parallelized paradigm confers inestimable utility for extensive biomarker verification campaigns and the systematic evaluation of voluminous sample cohorts.
- Mass Spectrometry (MS)
MS augments our microarray-centric paradigm. Ensuing enrichment and microarray-mediated capture, specimens routinely undergo MS-based deconstruction. This delivers granular architectural intelligence concerning glycan configurations and their precise loci of adduction. This synergistic strategy guarantees clients procure not merely a panoramic glycosylation profile, but concurrently, profound, site-resolved structural intelligence – a duality paramount for substantive scientific elucidation.
One Chip, Infinite Insights: Glycoproteomics Unfolded.
We provide customers with glycan microarray services to study the binding properties of potential glycan-binding proteins. We have the ability to analyze cells using high-throughput lectin microarrays, and can also be used to analyze the glycosylation characteristics of samples of interest. Our lectin microarrays include custom and semi-custom. Customized lectin microarray services use non-contact multi-channel printing equipment. The advantage of our customized service is that we can customize microarray products with a specific layout, size or substrate type. You can choose whether we can provide a glass slide substrate suitable for your sample, provide a customized substrate coating, or print directly on the substrate provided by the customer. You can choose probe samples from our internal glycan or lectin library, or provide your own samples as probes. After the microarray is made, you can also choose our microarray detection service, including sample pretreatment, hybridization, cleaning and data analysis.
Workflow
The microarray-based glycoproteomics service is executed through a streamlined, multi-step process to ensure a high level of quality and data integrity. Our typical workflow includes:
- Sample Preparation and Digestion
The process begins with the careful preparation of client samples, such as serum, cell lysates, or tissue extracts. Glycoproteins are often digested with proteases to generate a mixture of glycopeptides, which are more amenable to downstream analysis.
- Glycoprotein/Glycopeptide Enrichment
To focus the analysis, we enrich for glycoproteins or glycopeptides from the complex sample matrix. This is a critical step that removes non-glycosylated proteins, allowing for a deeper and more targeted analysis of the glycosylated components.
- Microarray Analysis
The enriched samples are then applied to our custom-designed lectin or protein microarrays. The labeled glycoproteins or glycopeptides bind to the immobilized probes (lectins, antibodies), and the resulting binding signals are detected and quantified using a high-sensitivity scanner.
- MS Integration
Following microarray analysis, the captured molecules can be further analyzed by mass spectrometry to determine the exact glycan structures and their corresponding protein sites. This provides unparalleled depth and confidence in the results.
- Data Acquisition and Analysis
The raw data from the microarray and mass spectrometer are meticulously processed and analyzed. We use advanced bioinformatics tools to provide comprehensive reports, including glycan profiles, differential expression analysis, and structural annotations.
Publication Data
DOI.: 10.1016/j.mcpro.2022.100433 External Link
Journal: Molecular & Cellular Proteomics
Published: 2022
Results: This research employed multi-lectin affinity chromatography and HILIC enrichment coupled with LC-MS/MS to profile the N-glycoproteome across normal, asymptomatic, and symptomatic Alzheimer's disease (AD) human brains. The study identified >300 glycoproteins and ~1,900 glycoforms, revealing that brain glycans are predominantly high-mannose structures (notably Man5, >20% of glycoforms) and bisected/fucosylated complex glycans, with minimal sialylation (<9%). Critically, site-specific glycosylation alterations were observed across AD stages, including changes in fucosylation frequency, bisection, and antennae number (e.g., increased branching in symptomatic AD). These findings highlight how glycoproteomics uncovers AD-associated glycan dysregulation, providing insights into disease mechanisms and potential biomarkers.
Advantages
- Our microarray platform enables the simultaneous analysis of thousands of binding events, allowing for rapid screening of large sample sets essential for biomarker discovery and validation studies.
- The reproducible nature of our microarray platform ensures the generation of reliable and comparable data across multiple experiments.
- Our optimized methods are highly sensitive for analyzing precious or scarce biological materials due to their capability with low-volume samples.
- Integrating microarray analysis with mass spectrometry provides both a broad overview of the glycome and detailed, site-specific structural information, ensuring a complete and accurate picture of glycosylation patterns.
Application
- Altered glycosylation is a hallmark of cancer. Our service can be used for the discovery of tumor-associated glycan biomarkers.
- Glycoproteins play a crucial role in host-pathogen interactions. Our platform can be used to study how glycosylation changes in response to viral or bacterial infections.
- Glycosylation changes have been linked to neurodegenerative diseases. Our service can aid in the discovery of glycan-based biomarkers for conditions like Alzheimer's and Parkinson's disease.
- Changes in glycosylation are often associated with chronic inflammation. Our service can help identify diagnostic and prognostic markers for autoimmune disorders and other inflammatory conditions.
Frequently Asked Questions
Associated Services
Microarray-based glycoproteomics service delivers high-resolution mapping of site-specific glycosylation across complex biological samples—revealing glycoform heterogeneity critical for biomarker discovery and therapeutic monitoring. To extend this structural precision into dynamic functional studies of glycan-mediated interactions, we offer the Liquid Glycan Display Array (LiGA) platform, which engineers fluidic membrane environments to mimic native cell-surface conditions. This integrated approach enables:
CD BioGlyco provides glycoproteomics services based on microarrays. We have a large team of scientists with a solid academic foundation and cooperate with researchers in basic biology and biomedical projects from all over the world. The advantage of choosing an analytical testing outsourcing testing service is that there is no need to consider any other costs (such as equipment and laboratory space), and it saves supervision or management. This advanced technology can quickly turn around and provide reliable results, thereby saving valuable time and resources. Please contact us for more detailed information.
Reference
- Suttapitugsakul, S.; et al. Glycoproteomics landscape of asymptomatic and symptomatic human Alzheimer's disease brain. Molecular & Cellular Proteomics. 2022, 21(12): 100433. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





